December 13, 2016 Amendment No. 1 to Amended and Restated Early Access Agreement with Impatients N.V

AMENDMENT NO. 1 TO

EARLY ACCESS AGREEMENT

This First Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of December 13, 2106 (the “Amendment No. 1 Effective Date”).

RECITALS

WHEREAS, HEMISPHERX and IMPATIENTS are Parties to and Early Access Agreement for HEMISPHERX’S Product, Ampligen (rintatolimod);

WHEREAS, the Parties wish to amend the Agreement as set forth below;

NOW, THEREFORE, the Parties hereby agree as follows:

Definitions and References. Except as set forth herein, capitalized terms not otherwise defined or amended in the Amendment shall have the meaning ascribed to them in the Agreement. References to Articles or Sections are the same with all of their subparts as they appear in the Agreement.

In Clause 1.10 the text “and/or treatment of pancreatic cancer” shall be added to the definition of Field, such that Clause 1.10 reads

“Field” means treatment of chronic fatigue syndrome and/or the treatment of pancreatic cancer.

In Exhibit 9 the text “for patients with Chronic Fatigue Syndrome” shall be added in the second line such that the first paragraph reads:

To the extent permitted by Applicable Law, IMPATIENTS shall use its reasonable commercial efforts to collect the following data in relation to the EAP for patients with Chronic Fatigue Syndrome;

IN WITNESS WHEREOF, the respective Parties hereto have duly executed this Amendment as of the Amendment No. 1 Effective Date above. The persons executing this Amendment represent and warrant that they have the full power and authority to enter into this Amendment on behalf of the persons or entities for whom they are signing.